Loading...
•
Mar 31, 2022
Altimmune Q1 2022 Earnings Report
Altimmune reported financial results for Q1 2022 and provided a corporate update.
Key Takeaways
Altimmune's Q1 2022 revenue was minimal, research and development expenses increased to $15.1 million, and net loss was $19.4 million, or $0.44 per share. The company's cash, cash equivalents, and restricted cash totaled $180.0 million as of March 31, 2022.
Pemvidutide's Phase 2 MOMENTUM trial enrollment is ongoing, with an interim analysis planned for Q4 2022.
Enrollment completed in Pemvidutide's Phase 1b NAFLD trial, with data readout expected in Q3 2022.
HepTcell's Phase 2 clinical trial in chronic hepatitis B is ongoing, with data readout expected in H1 2023.
Presentations summarizing Phase 1 trial data of pemvidutide at international Scientific Meetings are upcoming.
Altimmune
Altimmune
Forward Guidance
2022 operating expense guidance will be provided on the conference call.